[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-esophagitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-esophagitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100525366","phase-2-esomeprazole-and-radiation-induced-esophagitis-100525366",false,"NCT06120803","Esomeprazole and Radiation Induced Esophagitis","Effect of Esomeprazole on Radiation Induced Esophagitis in Non-small Cell Lung Cancer (EERENs): A Phase II Single Arm Study","EERENs","Inclusion Criteria:\n\n* Patient is ≥ 18 years of age.\n* Patient or patient's legal representative is willing and able to provide written informed consent and HIPAA authorization prior to performance of any study related activity.\n* Patient is willing and able to comply with scheduled visits and treatment schedules.\n* Patient has histopathologically confirmed diagnosis of NSCLC clinical stage III (as per the 8th edition of American Joint Committee on Cancer Staging).\n* Patients will receive thoracic radiation with estimated maximum dose to esophagus of at least 30 Gy (EQD2) in combination with concomitant chemotherapy.\n* Patient has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.\n* Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or urine HCG) within 2 weeks of enrollment).\n* Double inclusion in any ongoing trial (if the other trial permits) will be allowed.\n\nExclusion Criteria:\n\n* Patient has history of gastroesophageal junction or stomach cancer.\n* Patient has history of pre-existing severe or very severe dysphagia.\n* Patient has history of severe liver disease, acute or subacute systemic lupus erythematosus.\n* Patient has interstitial nephritis.\n* Patient has history of peptic ulcer disease.\n* Patient has prior history of upper gastrointestinal bleeding.\n* Patient has a history of thoracic radiotherapy within 2 years of enrollment.\n* Patient has known or suspected allergic response and prior adverse drug reaction with proton pump inhibitors.\n* Patient is currently on clopidogrel, nelfinavir, rilpivirine, methotrexate, rifampin, digoxin, tacrolimus, or phenytoin as these may have major drug interaction with esomeprazole.\n* Patients without concomitant chemoradiotherapy and with estimated maximum dose to esophagus of less than 30 Gy (EQD2).","ALL","18 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).",[27,28],"Radiation Esophagitis","Locally Advanced Lung Carcinoma","RECRUITING","2025-04-09",{"date":32,"type":33},"2025-04-13","ACTUAL",{"date":35,"type":33},"2024-03-01",{"date":37,"type":21},"2028-06-30",{"name":39,"class":40},"Rush University Medical Center","OTHER"]